Antioxidant administration prevents memory impairment in an animal model of maple syrup urine disease

Behavioural Brain Research

Volumn 231, Issue 1, 2012, Pages 92-96

  Scaini, Giselli ^a,b   Teodorak, Brena P ^a,b   Jeremias, Isabela C ^a,b   Morais, Meline O ^a,b   Mina, Francielle ^a,b   Dominguini, Diogo ^a,b   Pescador, Bruna ^a,b   Comim, Clarissa M ^a,b   Schuck, Patrícia F ^a   Ferreira, Gustavo C ^a   Quevedo, João ^a,b   Streck, Emilio L ^a,b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina INCT TM   (Brazil)

Author keywords

Antioxidants; Cognitive impairment; Inborn errors of metabolism; Maple syrup urine disease; SHIRPA

Indexed keywords

ACETYLCYSTEINE; BRANCHED CHAIN AMINO ACID; DEFEROXAMINE; ISOLEUCINE; LEUCINE; SODIUM CHLORIDE; VALINE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; AVOIDANCE MEMORY; BRAIN DAMAGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFICACY; EMOTIONALITY; LONG TERM MEMORY; MALE; MAPLE SYRUP URINE DISEASE; MEMORY; MEMORY CONSOLIDATION; MEMORY DISORDER; MENTAL HEALTH; MOTOR ACTIVITY; MUSCLE STRENGTH; MUSCLE TONE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; TREATMENT DURATION;

ACETYLCYSTEINE; AMINO ACIDS, BRANCHED-CHAIN; ANIMALS; ANTIOXIDANTS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; MALE; MAPLE SYRUP URINE DISEASE; MEMORY; MEMORY DISORDERS; RATS; RATS, WISTAR;

EID: 84859083891     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.03.004     Document Type: Article

References (53)

1. Chuang D.T., Shih V.E. Maple syrup urine disease (branched-chain ketoaciduria). The metabolic and molecular bases of inherited disease 2001, 1971-2005. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudt, W.L. Sly, D. Valle (Eds.).
2. Treacy E., Clow C.L., Reade T.R., Chitayat D., Mamer O.A., Scriver C.R. Maple syrup urine disease: interrelationship between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination. J Inherit Metab Dis 1992, 15:121-135.
3. Schonberger S., Schweiger B., Schwahn B., Schwarz M., Wendel U. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol Genet Metab 2004, 82:69-75.
4. Dodd P.R., Williams S.H., Gundlach A.L., Harper P.A., Healy P.J., Dennis J.A., et al. Glutamate and (-aminobutyric acid neurotransmitter systems in the acute phase of maple syrup urine disease and citrullinemia encephalopathies in newborn calves. J Neurochem 1992, 59:582-590.
5. Prensky A.L., Moser H.W. Changes in the amino acid composition of proteolipids of white matter during maturation of the human nervous system. J Neurochem 1967, 14:117-121.
6. Tavares R.G., Santos C.E.F., Tasca C., Wajner M., Souza D.O., Dutra-Filho C.S. Inhibition of glutamate uptake into synaptic vesicles of rat brain by the metabolites accumulating in maple syrup urine disease. J Neurol Sci 2000, 181:44-49.
7. Yudkoff M., Daikhin Y., Lin Z.P., Nissim I., Stern J., Pleasure D., et al. Interrelationships of leucine and glutamate metabolism in cultured astrocyts. J Neurochem 1994, 62:1192-1202.
8. Araújo P., Wassermann G.F., Tallini K., Furlanetto V., Vargas C.R., Wannmacher C.M., et al. Reduction of large neutral amino acid levels in plasma and brain of hyperleucinemic rats. Neurochem Int 2001, 38:529-537.
9. Danner D.J., Elsas L.J. Disorders of branched chain amino acid and keto acid metabolism. The metabolic basis of inherited disease 1989, 671-692. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
10. Halestrap A.P., Brand M.D., Denton R.M. Inhibition of mitochondrial pyruvate transport by phenylpyruvate and a-ketoisocaproate. Biochem Biophys Acta 1974, 367:102-108.
11. Land J.M., Mowbray J., Clark J.B. Control of pyruvate and h-hydroxybutyrate utilization in rat brain mitochondria and its relevance to phenylketonuria and maple syrup urine disease. J Neurochem 1976, 26:823-830.
12. Pilla C., Cardozo R.F., Dutra-Filho C.S., Wyse A.T., Wajner M., Wannmacher C.M. Creatine kinase activity from rat brain is inhibited by branched-chain amino acids in vitro. Neurochem Res 2003, 28:675-679.
13. Bridi R., Araldi J., Sgarbi M.B., Testa C.G., Durigon K., Wajner M., et al. Induction of oxidative stress in rat brain by the metabolites accumulating in maple syrup urine disease. Int J Dev Neurosci 2003, 21:327-332.
14. Bridi R., Braun C.A., Zorzi G.K., Wannmacher C.M., Wajner M., Lissi E.G., et al. Alpha-keto acids accumulating in maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats. Met Brain Dis 2005, 20:155-167.
15. Bridi R., Latini A., Braun C.A., Zorzi G.K., Wajner M., Lissi E.G., et al. Evaluation of the mechanisms involved in leucine induced oxidative damage in cerebral cortex of young rats. Free Radic Res 2005, 39:71-79.
16. Fontella F.U., Gassen E., Pulrolni V., Wannmacher C.M.D., Klein A.B., Wajner M., et al. Stimulation of lipid peroxidation in vitro in rat brain by the metabolites accumulating in maple syrup urine disease. Metab Brain Dis 2002, 17:47-54.
17. Mescka C., Moraes T., Rosa A., Mazzola P., Piccoli B., Jacques C., et al. In vivo neuroprotective effect of l-carnitine against oxidative stress in maple syrup urine disease. Metab Brain Dis 2011, 26:21-28.
18. Glaser V., Carlini V.P., Gabach L., Ghersi M., de Barioglio S.R., Ramirez O.A., et al. The intra-hippocampal leucine administration impairs memory consolidation and LTP generation in rats. Cell Mol Neurobiol 2010, 30:1067-1075.
19. Vasques Vde C., Brinco F., Wajner M. Intrahippocampal administration of the branched-chain alpha-hydroxy acids accumulating in maple syrup urine disease compromises rat performance in aversive and non-aversive behavioral tasks. J Neurol Sci 2005, 232:11-21.
20. Mello C.F., Feksa L., Brusque A.M., Wannmacher C.M., Wajner M. Chronic early leucine administration induces behavioral deficits in rats. Life Sci 1999, 65:747-755.
21. Moldeus P., Cotgreave I.A., Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986, 50:31-32.
22. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989, 6:593-597.
23. Sprong R.C., Winkelhuyzen-Janssen A.M.L., Aarsman C.J.M., van Oirschot J.F., Bruggen T., van Asbeck B.S. Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am J Respir Crit Care Med 1998, 157:1283-1293.
24. Ritter C., Andrades M.E., Reinke A., Menna-Barreto S., Moreira J.C., Dal-Pizzol F. Treatment with n-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit Care Med 2004, 32:342-349.
25. Damiani C.R., Benetton C.A., Stoffel C., Bardini K.C., Cardoso V.H., Di Giunta G., et al. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 2007, 22:1846-1851.
26. Di-Pietro P.B., Dias M.L., Scaini G., Burigo M., Constantino L., Machado R.A., et al. Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration. Neurosci Lett 2008, 434:139-143.
27. Bridi R., Fontella F.U., Pulrolnik V., Braun C.A., Zorzi G.K., Coelho D., et al. A chemically-induced acute model of maple syrup urine disease in rats for neurochemical studies. J Neurosci Methods 2006, 155:224-230.
28. Rogers D.C., Fisher E.M., Brown S.D., Peters J., Hunter A.J., Behavioral Martin J.E. functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 1997, 8:711-713.
29. Lackner P., Beer R., Heussler V., Goebel G., Rudzki D., Helbok R., et al. histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol 2006, 32:177-188.
30. Izquierdo I., Quillfeldt J.A., Zanatta M.S., Quevedo J., Schaeffer E., Schmitz P.K., et al. Sequential role of hippocampus and amygdala, entorhinal cortex and parietal cortex in formation and retrieval of memory for inhibitory avoidance in rats. Eur J Neurosci 1997, 9:786-793.
31. Quevedo J., Vianna M.R., Roesler R., De-Paris F., Izquierdo I., Rose S.P. Two time windows of anisomycin-induced amnesia for inhibitory avoidance training in rats: protection from amnesia by pretraining but not pre-exposure to the task apparatus. Learn Mem 1999, 6:600-607.
32. Izquierdo I., Barros D.M., Mello E., Souza T., de Souza M.M., Izquierdo L.A., et al. Mechanisms for memory types differ. Nature 1998, 393:635-636.
33. Barichello T., Martins M.R., Reinke A., Feier G., Ritter C., Quevedo J., et al. Cognitive impairment in sepsis survivors from cecal ligation, perforation. Crit Care Med 2005, 33:221-223.
34. Branco T., Meirelles R., da Rocha B.B., de Mattos-Dutra A., Wajner M., Pessoa-Pureur R. Alpha-ketoisocaproate increases the in vitro 32P incorporation into intermediate filaments in cerebral cortex of rats. Neuroreport 2000, 11:3545-4350.
35. Funchal C., de Lima Pelaez P., Loureiro S.O., Vivian L., Dall Bello Pessutto F., de Almeida L.M., et al. Alpha-ketoisocaproic acid regulates phosphorylation of intermediate filaments in postnatal rat cortical slices through ionotropic glutamatergic receptors. Brain Res Dev Brain Res 2002, 139:267-276.
36. Funchal C., Dall Bello Pessutto F., de Almeida L.M., de Lima Pelaez P., Loureiro S.O., Vivian L., et al. Alpha-keto-beta-methylvaleric acid increases the in vitro phosphorylation of intermediate filaments in cerebral cortex of young rats through the gabaergic system. J Neurol Sci 2004, 217:17-24.
37. Funchal C., Rosa A.M., Wajner M., Wofchuk S., Pureur R.P. Reduction of glutamate uptake into cerebral cortex of developing rats by the branched-chain alpha-keto acids accumulating in maple syrup urine disease. Neurochem Res 2004, 29:747-753.
38. Pessoa-Pureur R., Funchal C., de Lima Pelaez P., Vivian L., Oliveira Loureiro S., de Freitas Miranda R., et al. Effect of the branched-chain alpha-ketoacids accumulating in maple syrup urine disease on the high molecular weight neurofilament subunit (NF-H) in rat cerebral cortex. Metab Brain Dis 2002, 17:65-75.
39. Sgaravatti A.M., Rosa R.B., Schuck P.F., Ribeiro C.A., Wannmacher C.M., Wyse A.T., et al. Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease. Biochim Biophys Acta 2003, 1639:232-238.
40. Tashian R.E. Inhibition of brain-glutamic decarboxylase by phenylalanine, valine, and leucine derivatives: a suggestion concerning the etiology of the neurological defect in phenylketonuria and branched chain ketonuria. Metabolism 1961, 10:393-402.
41. Jouvet P., Rustin P., Taylor D.L., Pocock J.M., Felderhoff-Mueser U., Mazarakis N.D., et al. Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: implications for neurological impairment associated with maple syrup urine disease. Mol Biol Cell 2000, 11:1919-1932.
42. Izquierdo I., Medina J.H. Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem 1997, 68:285-316.
43. Bevilaqua L.R., Kerr D.S., Medina J.H., Izquierdo I., Cammarota M. Inhibition of hippocampal Jun N-terminal kinase enhances short-term memory but blocks long-term memory formation and retrieval of an inhibitory avoidance task. Eur J Neurosci 2003, 17:897-902.
44. Izquierdo I., Medina J.H. Correlation between the pharmacology of longterm potentiation and the pharmacology of memory. Neurobiol Learn Mem 1995, 63:19-32.
45. Bickford P.C., Shukitt-Hale B., Joseph J. Effects of aging on cerebellar noradrenergic function and motor learning: nutritional interventions. Mech Ageing Dev 1999, 111:141-154.
46. da Silva A.L., Piato A.L., Bardini S., Netto C.A., Nunes D.S., Elisabetsky E. Memory retrieval improvement by Ptychopetalum olacoides in young and aging mice. J Ethnopharmacol 2004, 95:199-203.
47. Serrano F., Klann E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev 2004, 3:431-443.
48. Carney J.M., Starke-Reed P.E., Oliver C.N., Landum R.W., Cheng M.S., Wu J.F., et al. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc Natl Acad Sci USA 1991, 88:3633-3636.
49. Carrillo M.C., Kanai S., Sato Y., Nokubo M., Ivy G.O., Kitani K. The optimal dosage of (-) deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci 1993, 52:1925-1934.
50. Knoll J., Yen T.T., Miklya I. Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference. Life Sci 1994, 54:1047-1057.
51. Amyloid-beta Kontush A. an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 2001, 31:1120-1131.
52. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997, 23:134-147.
53. Small G.W. Treatment of Alzheimer's disease, current approaches and promising developments. Am J Med 1998, 104:32S-38S.